Müller C, Pehamberger H, Binder M, Zielinski C C
II. Department of Gastroenterology and Hepatology, University of Vienna, Austria.
J Cancer Res Clin Oncol. 1989;115(4):393-6. doi: 10.1007/BF00400969.
Unstimulated and interferon (IFN)-stimulated natural killer cell (NK) activity was investigated in patients with malignant melanoma prior to the removal of the primary melanoma (stage I disease) or in patients with melanoma metastases. Unstimulated as well as IFN-stimulated NK activities, directed against the primarily NK-sensitive K562 cell line, were found not to differ significantly from the NK activity of healthy control subjects. In contrast, IFN-stimulated NK activity directed against the primarily NK-insensitive Chang hepatoma and JY cell lines was significantly lower in patients with metastatic melanoma than in patients with non-metastatic disease (Chang hepatoma cell line: P less than 0.02; JY cell line: P less than 0.0017) and - in experiments using the JY cell line - than in healthy controls (P less than 0.01). Stage I melanoma patients did not differ in their IFN-induced NK activity from healthy control subjects using Chang hepatoma and JY cell lines. Finally, the IFN-induced increase in NK activity directed against primarily NK-insensitive target cell lines was significant in stage I melanoma patients and in healthy controls (P less than 0.01, respectively), but not in patients with metastatic melanoma (P greater than 0.5). We thus conclude that patients with metastatic malignant melanoma exhibited a defect in IFN-augmented NK activity directed against primarily NK-insensitive targets.
在原发性黑色素瘤切除前的恶性黑色素瘤患者（I期疾病）或黑色素瘤转移患者中，研究了未刺激状态和干扰素（IFN）刺激状态下的自然杀伤细胞（NK）活性。针对主要对NK敏感的K562细胞系，未刺激状态以及IFN刺激状态下的NK活性，与健康对照受试者的NK活性相比，未发现显著差异。相比之下，针对主要对NK不敏感的Chang肝癌细胞系和JY细胞系，转移性黑色素瘤患者中IFN刺激的NK活性显著低于非转移性疾病患者（Chang肝癌细胞系：P<0.02；JY细胞系：P<0.0017），并且——在使用JY细胞系的实验中——低于健康对照（P<0.01）。使用Chang肝癌细胞系和JY细胞系时，I期黑色素瘤患者的IFN诱导NK活性与健康对照受试者没有差异。最后，针对主要对NK不敏感的靶细胞系，IFN诱导的NK活性增加在I期黑色素瘤患者和健康对照中具有显著性（分别为P<0.01），但在转移性黑色素瘤患者中不具有显著性（P>0.5）。因此，我们得出结论，转移性恶性黑色素瘤患者在针对主要对NK不敏感的靶标的IFN增强NK活性方面存在缺陷。
